Group 1 - The core viewpoint of the report is that due to the upfront payment from the collaboration with BMS, the company has raised its 2026 profit forecast by 228% to USD 0.62 billion and introduced a new profit forecast for 2027 at USD 0.60 billion [1] - The target price has been increased by 34.3% to HKD 18.00, indicating a potential upside of 44.5% from the current stock price [1] Group 2 - The company announced a long-term strategic partnership with Blue Nanotech on December 29, 2025, to advance the development of next-generation radionuclide drug conjugates (RDCs) [2] - The proprietary Harbour Mice platform allows the company to produce fully human monoclonal antibodies in H2L2 and HCAb formats, which have lower immunogenicity, superior tissue penetration, and high specificity and stability, enhancing the efficacy of RDC drugs while reducing side effects [3] - The company has established multiple overseas licensing collaborations, including a long-term global strategic cooperation agreement with BMS on December 17, 2025, which includes an upfront payment of USD 90 million and potential milestone payments of up to USD 1.035 billion [3] - A non-exclusive licensing agreement was signed with Pfizer on November 19, 2025, for advancing preclinical antibody discovery for various potential diseases, with upfront payments and milestone payments based on regulatory, clinical, and commercialization achievements [3] - The collaboration with AstraZeneca was further deepened on November 24, 2025, expanding the scope to include ADC and TCE drugs [3]

Core Viewpoint - The announcement by Heptares Therapeutics regarding its subsidiary Nona Biosciences entering a non-exclusive licensing agreement with Pfizer to advance preclinical antibody discovery for various potential disease indications [1] Group 1: Agreement Details - Nona Biosciences grants Pfizer global rights to utilize its proprietary HCAb platform for the development of fully human only heavy chain antibodies [1] - Nona Biosciences will receive an upfront payment and is entitled to regulatory, clinical, and commercial milestone payments [1] - The collaboration allows Nona Biosciences to leverage its HCAb platform, advanced B cell screening technology, and comprehensive services for antibody discovery, development, and engineering [1]

Core Viewpoint - The stock of Heptagon Pharmaceuticals-B (02142) rose over 6% following the announcement of a non-exclusive licensing agreement between its subsidiary, Nona Bio, and Pfizer to advance preclinical antibody discovery for various potential disease indications [1] Group 1: Company Developments - Heptagon Pharmaceuticals-B's stock increased by 6.16%, reaching HKD 14.68, with a trading volume of HKD 8.0214 million [1] - Nona Bio, a wholly-owned subsidiary of Heptagon Pharmaceuticals-B, has entered into a non-exclusive licensing agreement with Pfizer [1] - The agreement allows Pfizer to utilize Nona Bio's proprietary HCAb platform globally for the development of fully human only heavy chain antibodies [1] Group 2: Financial Implications - Nona Bio will receive an upfront payment from Pfizer and is entitled to receive regulatory, clinical, and commercial milestone payments [1] - The collaboration will leverage Nona Bio's HCAb platform, advanced B cell screening technology, and comprehensive services for antibody discovery, development, and engineering [1]

Core Viewpoint - Heptares Therapeutics-B (02142) shares rose over 6% in early trading, reaching HKD 14.68 with a trading volume of HKD 8.0214 million following the announcement of a non-exclusive licensing agreement with Pfizer to advance preclinical antibody discovery for various potential disease indications [1]. Group 1 - Heptares Therapeutics-B's subsidiary, Nona Bio (Suzhou) Co., Ltd., has entered into a non-exclusive licensing agreement with Pfizer [1]. - The agreement allows Pfizer to gain global rights to Nona Bio's proprietary HCAb platform for the development of fully human only heavy chain antibodies [1]. - Nona Bio will receive an upfront payment and is entitled to regulatory, clinical, and commercial milestone payments [1]. Group 2 - Nona Bio will collaborate with Pfizer to utilize its HCAb platform, advanced B cell screening technology, and comprehensive services for antibody discovery, development, and engineering [1].

Core Viewpoint - The announcement highlights a strategic partnership between the company’s subsidiary, Nona Bio, and Pfizer to advance preclinical antibody discovery for various potential disease indications [1] Group 1: Agreement Details - Nona Bio has entered into a non-exclusive licensing agreement with Pfizer, granting Pfizer global rights to utilize Nona Bio's proprietary HCAb platform for the development of fully human only heavy chain antibodies [1] - Nona Bio will receive an upfront payment and is entitled to receive regulatory, clinical, and commercial milestone payments as part of the agreement [1] Group 2: Collaboration Aspects - The collaboration allows Nona Bio to work with Pfizer, leveraging its HCAb platform, advanced B cell screening technology, and comprehensive services for antibody discovery, development, and engineering [1]

Core Viewpoint - The announcement highlights a non-exclusive licensing agreement between Nona Bio, a wholly-owned subsidiary of HAPO (02142), and Pfizer to advance preclinical antibody discovery for various potential disease indications [1] Group 1: Agreement Details - Pfizer will gain global rights to utilize Nona Bio's proprietary HCAb platform for the development of fully human only heavy chain antibodies [1] - Nona Bio will receive an upfront payment and is entitled to regulatory, clinical, and commercial milestone payments [1] - The collaboration allows Nona Bio to leverage its HCAb platform, advanced B cell screening technology, and comprehensive services for antibody discovery, development, and engineering [1]

Core Viewpoint - The company, Heptagon Pharmaceuticals-B (02142.HK), has entered into a non-exclusive licensing agreement with Pfizer to advance preclinical antibody discovery for various potential disease indications [1] Group 1: Agreement Details - Heptagon's wholly-owned subsidiary, Nona Biotech (Suzhou) Co., Ltd., will provide Pfizer with global access to its proprietary HCAb platform for the development of fully human only heavy chain antibodies [1] - Nona Biotech will receive an upfront payment and is entitled to receive regulatory, clinical, and commercial milestone payments [1] - The collaboration allows Nona Biotech to utilize its HCAb platform, advanced B cell screening technology, and comprehensive services for antibody discovery, development, and engineering [1]